Document Detail

Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
MedLine Citation:
PMID:  18430789     Owner:  NLM     Status:  MEDLINE    
The cytotoxicity of the monofunctional alkylator temozolomide (TMZ) is mediated by mismatch repair (MMR) triggered by O(6)-alkylguanine, whereas MMR protects cells against bifunctional alkylators, including carmustine (BCNU). Therefore, TMZ may be cytotoxic to BCNU-resistant cancer cells because MMR affects sensitivity to TMZ and BCNU in a converse way. We evaluated TMZ cytotoxicity on BCNU-resistant variant (CEM-R) compared with the parental CCRF-CEM cell line (CEM-S). The mechanisms of its BCNU-resistance involved DNA repairs including nucleotide excision repair, base excision repair, alkylguanine alkyltransferase, MMR, and apoptotic and survival pathways. In particular, transcript levels of MMR-related hMLH1 and hMSH2 were enhanced in CEM-R cells. CEM-R cells were 8-fold more BCNU-resistant but surprisingly 9-fold more TMZ-sensitive than were CEM-S cells. Although TMZ-induced adducts include N-alkylated purines and O(6)-alkylguaine, DNA excision repair was enhanced in CEM-R cells, suggesting the efficient repair of N-alkylation adducts. Cotreatment with methoxyamine, a base excision repair inhibitor, did not sensitize CEM-R cells to TMZ, suggesting little or no contribution of N-alkylation to TMZ-induced cytotoxicity. Cotreatment with O(6)-benzylguanine, an alkylguanine alkyltransferase inhibitor, further sensitized CEM-R cells to TMZ, confirming the cytotoxic impact of O(6)-alkylguanine. Cotreatment with cadmium chloride, an MMR inhibitor, disrupted the sensitivity of CEM-R cells to TMZ. The sensitivity to TMZ was reversed in the CEM-R variant clone that had been established by transfecting CEM-R cells with short hairpin hRNA against hMLH1, suggesting the critical role of MMR on sensitization to TMZ. In conclusion, BCNU-resistant CEM-R cells were sensitized to TMZ as a result of enhanced MMR during the development of BCNU resistance.
Takahiro Yamauchi; Masami Ogawa; Takanori Ueda
Related Documents :
18559539 - Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-te...
10419559 - Effect of loss of dna mismatch repair on development of topotecan-, gemcitabine-, and p...
19428379 - Inhibition of homologous recombination by treatment with bvdu (brivudin) or by rad51 si...
2439199 - Nucleolar protein b23 translocation after doxorubicin treatment in murine tumor cells.
9398059 - Characterisation of novel human lung carcinoma cell lines selected for resistance to an...
9754649 - P-glycoprotein-mediated methotrexate resistance in ccrf-cem sublines deficient in metho...
23181159 - Precursors linked via the zipper-like structure or the filopodium during the secondary ...
7929969 - Genetic evaluation of somatic cell scores for united states dairy cattle.
22524189 - Infrared microspectroscopy of living cells in microfluidic devices (md-irms): toward a ...
Publication Detail:
Type:  Journal Article     Date:  2008-04-22
Journal Detail:
Title:  Molecular pharmacology     Volume:  74     ISSN:  1521-0111     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-20     Completed Date:  2008-07-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  82-91     Citation Subset:  IM    
Department of Hematology and Oncology, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji, Fukui 910-1193, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Alkylating / administration & dosage,  pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Apoptosis / drug effects
Cadmium Chloride / administration & dosage
Carmustine / pharmacology
Cell Line, Tumor
Cell Proliferation / drug effects
Comet Assay
DNA Mismatch Repair / drug effects*
Dacarbazine / analogs & derivatives*,  pharmacology
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm / physiology
Guanine / administration & dosage,  analogs & derivatives
Hydroxylamines / administration & dosage
Nimustine / administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*,  genetics,  metabolism,  pathology
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Hydroxylamines; 10108-64-2/Cadmium Chloride; 154-93-8/Carmustine; 19916-73-5/O(6)-benzylguanine; 42471-28-3/Nimustine; 4342-03-4/Dacarbazine; 67-62-9/methoxyamine; 73-40-5/Guanine; 85622-93-1/temozolomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]pro...
Next Document:  Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent fami...